| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 14, 2003
Revised on February 20, 2004
Accepted on February 23, 2004
From the Department of Anatomy (F.B., M.R.-D., T.L., D.M.M.), Cardiovascular Research Institute and Comprehensive Cancer Center, University of California, San Francisco, Calif; Regeneron Pharmaceuticals (G.T.), Tarrytown, NY; University of Texas (R.B.), Southwestern Medical Center, Dallas, Tex.
* To whom correspondence should be addressed. E-mail: dmcd{at}itsa.ucsf.edu.
Vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang1) are essential for vascular development, but this dependency has been assumed not to persist into adult life. In this study, we report that after 10 days of systemic treatment of 4-, 8-, and 16-week-old mice with VEGF-Trap, an inhibitor of VEGF, the number of capillaries in the tracheal mucosa was reduced by 39%, 28%, and 14%, respectively. The magnitude of the reduction decreased with age (r2=0.6, P<0.001), but was still significant at 16 weeks. A corresponding age-related decrease in vascular endothelial growth factor receptor-2 (VEGFR-2) immunoreactivity suggests that diminished VEGFR-2 expression may contribute to resistance to VEGF signaling inhibition. VEGF-Trap further reduced VEGFR-2 expression in tracheal capillaries. By comparison, systemic treatment with adenovirus encoding Ang1 led to a significant enlargement of tracheal venules with little age effect (64%, 56%, and 49% increase in diameter at 10 days). When Ang1 was given in combination with VEGF-Trap, tracheal vessels presented the typical response to each factor, showing that the Ang1 effect was not VEGF-mediated, yet Ang1 seems to have a protective effect, as judged by prevention of VEGF-Trap-induced reduction in tracheal capillaries in the oldest group. Together, these findings indicate that VEGF and Ang1 participate in blood vessel survival and plasticity in adult life.
This article has been cited by other articles:
![]() |
M. L. Maitland, K. E. Kasza, T. Karrison, K. Moshier, L. Sit, H. R. Black, S. D. Undevia, W. M. Stadler, W. J. Elliott, and M. J. Ratain Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment Clin. Cancer Res., October 1, 2009; 15(19): 6250 - 6257. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Okazaki, A. Ni, P. Baluk, O. A. Ayeni, J. Kearley, A. J. Coyle, A. Humbles, and D. M. McDonald Capillary Defects and Exaggerated Inflammatory Response in the Airways of EphA2-Deficient Mice Am. J. Pathol., June 1, 2009; 174(6): 2388 - 2399. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. Olfert, R. A. Howlett, K. Tang, N. D. Dalton, Y. Gu, K. L. Peterson, P. D. Wagner, and E. C. Breen Muscle-specific VEGF deficiency greatly reduces exercise endurance in mice J. Physiol., April 15, 2009; 587(8): 1755 - 1767. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Cuddihy, S. Ge, J. Zhu, J. Jang, A. Chidgey, G. Thurston, R. Boyd, and G. M. Crooks VEGF-mediated cross-talk within the neonatal murine thymus Blood, March 19, 2009; 113(12): 2723 - 2731. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S.N. Shim, I. A.W. Ho, and P. E.H. Wong Angiopoietin: A TIE(d) Balance in Tumor Angiogenesis Mol. Cancer Res., July 1, 2007; 5(7): 655 - 665. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Srivastava, V. Kundumani-Sridharan, B. Zhang, A. K. Bajpai, and G. N. Rao 15(S)-Hydroxyeicosatetraenoic Acid-Induced Angiogenesis Requires STAT3-Dependent Expression of VEGF Cancer Res., May 1, 2007; 67(9): 4328 - 4336. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Senan and E. F. Smit Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy Oncologist, April 1, 2007; 12(4): 465 - 477. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Eun Kim, C.-H. Cho, H.-Z. Kim, P. Baluk, D. M. McDonald, and G. Young Koh In Vivo Actions of Angiopoietins on Quiescent and Remodeling Blood and Lymphatic Vessels in Mouse Airways and Skin Arterioscler Thromb Vasc Biol, March 1, 2007; 27(3): 564 - 570. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.A. Goodlad, A.J. Ryan, S.R. Wedge, I.T. Pyrah, D. Alferez, R. Poulsom, N.R. Smith, N. Mandir, A.J. Watkins, and R.W. Wilkinson Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer Carcinogenesis, October 1, 2006; 27(10): 2133 - 2139. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Karpanen, M. Wirzenius, T. Makinen, T. Veikkola, H. J. Haisma, M. G. Achen, S. A. Stacker, B. Pytowski, S. Yla-Herttuala, and K. Alitalo Lymphangiogenic Growth Factor Responsiveness Is Modulated by Postnatal Lymphatic Vessel Maturation Am. J. Pathol., August 1, 2006; 169(2): 708 - 718. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Saint-Geniez, A. E. Maldonado, and P. A. D'Amore VEGF Expression and Receptor Activation in the Choroid during Development and in the Adult. Invest. Ophthalmol. Vis. Sci., July 1, 2006; 47(7): 3135 - 3142. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. P.J. Brindle, P. Saharinen, and K. Alitalo Signaling and Functions of Angiopoietin-1 in Vascular Protection Circ. Res., April 28, 2006; 98(8): 1014 - 1023. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Campochiaro and the First ARVO/Pfizer Institute Working Group Ocular versus Extraocular Neovascularization: Mirror Images or Vague Resemblances Invest. Ophthalmol. Vis. Sci., February 1, 2006; 47(2): 462 - 474. [Full Text] [PDF] |
||||
![]() |
T. Nakahara, S. M. Norberg, D. R. Shalinsky, D. D. Hu-Lowe, and D. M. McDonald Effect of Inhibition of Vascular Endothelial Growth Factor Signaling on Distribution of Extravasated Antibodies in Tumors Cancer Res., February 1, 2006; 66(3): 1434 - 1445. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kamba, B. Y. Y. Tam, H. Hashizume, A. Haskell, B. Sennino, M. R. Mancuso, S. M. Norberg, S. M. O'Brien, R. B. Davis, L. C. Gowen, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H560 - H576. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Baffert, T. Le, B. Sennino, G. Thurston, C. J. Kuo, D. Hu-Lowe, and D. M. McDonald Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H547 - H559. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Adamson and F. E. Curry Ang-1: Tie-ing up endothelial adhesion? Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H74 - H76. [Full Text] [PDF] |
||||
![]() |
F. Baffert, T. Le, G. Thurston, and D. M. McDonald Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H107 - H118. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. McDonald and P. Baluk Imaging of Angiogenesis in Inflamed Airways and Tumors: Newly Formed Blood Vessels Are Not Alike and May Be Wildly Abnormal: Parker B. Francis Lecture Chest, December 1, 2005; 128(6_suppl): 602S - 608S. [Full Text] [PDF] |
||||
![]() |
G. Thurston, Q. Wang, F. Baffert, J. Rudge, N. Papadopoulos, D. Jean-Guillaume, S. Wiegand, G. D. Yancopoulos, and D. M. McDonald Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental period Development, July 15, 2005; 132(14): 3317 - 3326. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Cho, K. E. Kim, J. Byun, H.-S. Jang, D.-K. Kim, P. Baluk, F. Baffert, G. M. Lee, N. Mochizuki, J. Kim, et al. Long-Term and Sustained COMP-Ang1 Induces Long-Lasting Vascular Enlargement and Enhanced Blood Flow Circ. Res., July 8, 2005; 97(1): 86 - 94. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tammela, A. Saaristo, M. Lohela, T. Morisada, J. Tornberg, C. Norrmen, Y. Oike, K. Pajusola, G. Thurston, T. Suda, et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia Blood, June 15, 2005; 105(12): 4642 - 4648. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tammela, B. Enholm, K. Alitalo, and K. Paavonen The biology of vascular endothelial growth factors Cardiovasc Res, February 15, 2005; 65(3): 550 - 563. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-P. Gerber and N. Ferrara Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies Cancer Res., February 1, 2005; 65(3): 671 - 680. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy Science, January 7, 2005; 307(5706): 58 - 62. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Inai, M. Mancuso, H. Hashizume, F. Baffert, A. Haskell, P. Baluk, D. D. Hu-Lowe, D. R. Shalinsky, G. Thurston, G. D. Yancopoulos, et al. Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts Am. J. Pathol., July 1, 2004; 165(1): 35 - 52. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |